Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2003 (Fiscal Year 2004, Q1 and H1).
Business Overview: A diversified healthcare services company operating in four segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Dec 31, 2003 | 6 Months Ended Dec 31, 2003 |
|---|---|---|
| Operating Revenue | $14,093.6 | $27,381.9 |
| Operating Earnings | $587.3 | $1,109.7 |
| Net Earnings | $375.8 | $704.4 |
| Diluted EPS | $0.86 | $1.59 |
| Operating Cash Flow (6 mo) | $548.4 | $548.4 |
| Cash and Equivalents (End of Period) | $544.3 | $544.3 |
| Total Debt (Current + Long-term) | $2,725.6 | $2,725.6 |
Note: Total Debt calculated as Notes payable ($1.5M) + Current portion of long-term obligations ($251.7M) + Long-term obligations ($2,472.4M).
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 11% for the quarter and 14% for the six-month period compared to the prior year, driven by volume growth and new customer agreements across all segments.
- Earnings Performance: Operating earnings decreased 1% for the quarter but increased 5% for the six-month period. The quarterly decline was primarily due to a reduction in special item income compared to the prior year.
- Segment Performance:
- Pharmaceutical Distribution: Operating earnings declined 8% (quarter) due to a transition from a "buy and hold" inventory model to a "just-in-time" fee-for-service model, causing temporary margin mismatches.
- Pharmaceutical Technologies: Revenue surged 58% and operating earnings grew 33% (quarter), aided by the inclusion of Syncor International Corporation (acquired Jan 1, 2003) and strong demand in packaging and oral technologies.
- Special Items: Net special items resulted in $3.5 million of income for the quarter and $9.7 million of expense for the six months, compared to $37.6 million of income and $18.9 million of income in the prior year periods. This shift was largely due to litigation settlement income of $24.2 million in the current quarter versus $89.9 million in the prior year quarter.
Guidance, Outlook, and Risks
- Business Model Transition: Management expects the transition to the "just-in-time" model in the Pharmaceutical Distribution segment to continue through the remainder of fiscal 2004 and into fiscal 2005. They anticipate the most severe margin mismatches occurred in the quarter ended December 31, 2003, and do not expect the earnings decline trend to continue.
- Acquisitions: Completed acquisitions of Intercare Group, plc ($570 million) and Medicap Pharmacies, Inc. ($69 million) in December 2003. The company intends to continue seeking opportunities to expand its service role in healthcare.
- Capital Allocation: The company repurchased approximately 17.0 million shares for $1.0 billion during the quarter. Shareholders' equity declined by $165.8 million primarily due to this buyback and dividends.
- Legal and Regulatory Risks:
- Syncor Litigation: Multiple shareholder lawsuits and an SEC informal inquiry regarding Syncor's accounting practices and improper payments. Management believes the impact will not be material.
- Latex Litigation: Pending lawsuits regarding natural rubber latex exposure. Potential liability estimated between $0 and $20 million net of insurance.
- Medicare Act: The new Medicare Prescription Drug Act (enacted Dec 2003) is expected to create additional volume demand and incentives for generic drug utilization.
Investor Verification Checklist
- Margin Sustainability: Verify the timeline and financial impact of the "just-in-time" business model transition in the Pharmaceutical Distribution segment.
- Special Items Volatility: Assess the reliance on litigation settlements (vitamins and pharmaceutical antitrust) for earnings stability, given the significant year-over-year fluctuation.
- Syncor Integration: Monitor the resolution of Syncor-related legal proceedings and the integration costs, estimated at an additional $70 million in future periods.
- Cash Flow vs. Capital Return: Review the sustainability of the $1.0 billion share repurchase program alongside the $658 million cash used in investing activities for acquisitions.
- Inventory Levels: Analyze the $861.3 million increase in inventories over six months in the context of the stated shift away from inventory accumulation.